Respicardia
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Respicardia sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Respicardia: 8 sponsored US clinical trials, none currently recruiting.
Respicardia sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Central Sleep Apnea, with 2 trials.
Upper-quartile sponsor footprint
Respicardia sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
8 total, page 1 of 1
remedē System Therapy Study
NCT03884660
Janus Feasibility Study
NCT03985527
Post Approval Study of the remedē System
NCT03425188
Respicardia, Inc. Pivotal Trial of the remedē System
NCT01816776
Prospective Evaluation of Heart Failure Patients With Central Sleep Apnea
NCT01414309
Chronic Evaluation of Respicardia Therapy
NCT01124370
Identification of the Pericardiophrenic Vein During Cardiac Device Implant Procedures to Prevent Extracardiac Stimulation
NCT01008670
Feasibility Study to Determine the Effects of Phrenic Nerve Stimulation in Patients With Periodic Breathing
NCT00909259
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Therapeutic Areas
How the Respicardia early-phase archive is shaped
8 indexed studies, none listed as recruiting (0% open); 6 completed (75%).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Central Sleep Apnea (2 trials), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Respicardia: archived-pipeline peers nationwide
Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Respicardia sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 archived trials
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Respicardia page
8 registered trials is a research-attention snapshot, not an endorsement of Respicardia or any single study.
- None of Respicardia's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Central Sleep Apnea is the condition Respicardia studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Central Sleep Apnea trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Respicardia pipeline card: 8 registered trials from official public datasets.Report a data error.